Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Placebo|BIOLOGICAL: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Sponsor: Merck Sharp & Dohme LLC